LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Aandelen Lijst・Roivant Sciences Ltd
Search

Roivant Sciences Ltd

Gesloten

SectorGezondheidszorg

28.4 -2.27

Strong Buy

Prijsupdate 10 jun 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.3

Max

29.31

Belangrijke statistieken

By Trading Economics

Inkomsten

669M

356M

Verkoop

521K

2.5M

Winstmarge

14,116.825

Werknemers

721

EBITDA

-65M

-354M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+25.75% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

255M

20B

Vorige openingsprijs

30.67

Vorige sluitingsprijs

28.4

Nieuwssentiment

By Acuity

24%

76%

50 / 344 Rangschikking in Healthcare

Roivant Sciences Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jun 2026, 23:36 UTC

Winsten

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Lezen

10 jun 2026, 23:19 UTC

Populaire aandelen

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Lezen

10 jun 2026, 23:09 UTC

Belangrijke Marktbewegers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Lezen

10 jun 2026, 23:04 UTC

Winsten

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Lezen

10 jun 2026, 20:44 UTC

Belangrijke Marktbewegers

Caterpillar Raises Quarterly Dividend 8%

DJ

Lezen

10 jun 2026, 23:49 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Should Take No Options Off The Table

DJ

Lezen

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Lezen

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Lezen

10 jun 2026, 23:47 UTC

Marktinformatie

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Lezen

10 jun 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Lezen

10 jun 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Lezen

10 jun 2026, 23:32 UTC

Marktinformatie

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Lezen

10 jun 2026, 23:20 UTC

Marktinformatie

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Lezen

10 jun 2026, 22:05 UTC

Marktinformatie

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Lezen

10 jun 2026, 21:57 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:52 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:35 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:22 UTC

Winsten

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:39 UTC

Marktinformatie
Winsten

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Lezen

10 jun 2026, 20:34 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 20:33 UTC

Winsten

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Lezen

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Roivant Sciences Ltd Prognose

Koersdoel

By TipRanks

25.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 36.53 USD  25.75%

Hoogste 42 USD

Laagste 29.29 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Roivant Sciences Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Roivant Sciences Ltd - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

50 / 344 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat